clinical trial · NCT05759208
The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease
Dry Eye DiseaseOK-101Placebo
brief summary
The objective of this study is to compare the safety and efficacy of OK-101 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.
started
Apr 28, 2023
primary completion
Dec 15, 2023
completion
Dec 15, 2023
last updated
Feb 9, 2024
detailed description
Subjects eligible to be randomized will receive either OK-101 or placebo to be administered bilaterally twice daily (BID) for 12 weeks (from Visit 2 to Visit 5). During a 14-day study run-in period (for the purpose of subject selection) prior to randomization, all subjects will receive Placebo Ophthalmic Solution (vehicle) bilaterally BID.
official title
A Phase 2, Multi-center, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Efficacy and Safety of OK-101 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol